Manufacturing

Felicity Thomas is Associate Editorial Director of Pharmaceutical Technology, Pharmaceutical Technology Europe, BioPharm International.

Articles

Technological advances will help ease pressure on pharma supply chains, allowing for greater visibility and less uncertainty.

Keeping Europe’s Medicines Stocked

Siegfried Schmitt, PhD, is Vice President Technical at Parexel International, Siegfried.Schmitt@parexel.com.

Good distribution practices ensure appropriate physical storage, distribution, and supply chain security, says Siegfried Schmitt, vice president, Technical, at Parexel.

Securing the Supply Chain with Good Distribution Practices

Suzanne Shelley is contibuting editor to 

Efforts to optimize the delivery of sensitive biotherapeutics continue to evolve.

Safeguarding Biologics—Blending Engineering Ingenuity and Managerial Excellence

Bio/pharma has evolved and adapted to a variety of challenges in 2022, but what might be on the cards for the industry in 2023?

Opening Up Opportunities in 2023

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

mRNA may not be a train we necessarily all need to get onboard immediately, but we should know where the central train station is located, and what it connects us to.

mRNA Hauptbahnhof

High-cost-per-dose large molecules can make a big impact on cell and gene therapy supply chain management.

Drug Product Security

The newly formed partnership between CSafe and BioLife will expand cold chain supply chain solutions for the cell and gene therapy market.

CSafe and BioLife Solutions Partnership Will Expand Supply Chain for Cell and Gene Therapies

Adam Andersen, executive vice president, Pharma, at Informa—the event organizer behind CPHI Frankfurt.

Pharma supply chains are no longer hidden beyond the reach of ESG agendas, making it important for companies to accelerate adoption of new manufacturing processes and environmental technology

At the Heart of Pharma: ESG has Arrived as a Central Strategy 

Cleo Bern Hartley is a pharma consultant, former pharma analyst, and research scientist.

Biopharma focuses on streamlining biomanufacturing and supply chain issues to drive uptake of cell and gene therapies.

Growth in Cell and  Gene Therapy Market

Alasdair Leckie is operations director at Rephine Ltd, a firm of deeply experienced GMP auditors which proactively help pharmaceutical companies around the world with their supply-chain quality assurance. Alasdair has been with Rephine for nine years and has a Bachelor’s Degree in Chinese and Economics from SOAS University of London.

A new survey has demonstrated that remote audits, brought to the fore thanks to COVID-19, are not necessarily a preferred option for clients. 